Norway's Aker BioMarine Q1 revenue rises 13% on record krill oil sales

Aker Biomarine ASA

30/04/2026 06:14

Overview

Norway krill-derived health products maker's Q1 revenue rose 13% yr/yr to $57.3 mln

Adjusted EBITDA for Q1 grew 34% yr/yr to $12.5 mln

Krill oil revenues hit all-time high, supported by higher volumes and improved price mix

Outlook

Company expects continued YoY growth in Human Health Ingredients segment, supported by strong demand

Consumer Health Products revenues expected to return to modest growth

Company is exploring strategic alternatives for Human Health Ingredient business unit, targeting a transaction in 2026

Result Drivers

KRILL OIL DEMAND - Record krill oil revenues driven by strong demand, higher volumes and improved price mix, per CEO Matts Johansen

HUMAN HEALTH INGREDIENTS GROWTH - Segment revenue up 22% yr/yr, mainly on higher krill oil volumes and improved price mix

CONSUMER HEALTH PRODUCTS DECLINE - Segment revenue fell 2% yr/yr, as Epion's ongoing marketing repositioning weighed on short-term sales

Company press release: ID:nObi1byVka

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$57.3 mln
$59.50 mln (2 Analysts)
Q1 Adjusted EBITDA
$12.5 mln
$14 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the fishing & farming peer group is "buy"

Wall Street's median 12-month price target for Aker Biomarine ASA is NOK122.50, about 24.5% above its April 29 closing price of NOK98.40

The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 39 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)